Preserved pulsatility and the IGF-1 axis

A longer pulse that still returns to baseline, and where the fat goes

The central pharmacologic argument for tesamorelin is a shape, not a size. It amplifies the body’s own GH pulses instead of holding growth hormone high and flat, so hypothalamic feedback stays in charge. That shape does not make the rise small: the FDA label reports IGF-1 above 2 standard deviation scores in 47 percent of treated patients at 26 weeks, which is why IGF-1 is monitored rather than assumed safe.

This unit contrasts pulsatile with sustained signaling, follows the feedback loops that make tesamorelin self-limiting, traces the IGF-1 rise over weeks, and shows how that IGF-1 drives lipolysis of visceral fat.